PHILADELPHIA – Data presented at the American Academy of Neurology (AAN) meeting this week on experimental therapeutics for Huntington's disease gave some cause for optimism. And, as good research does, they identified new questions as they answered current ones. Read More
Almost nine years after its complete response letter (CRL) from the FDA for tafamidis, Pfizer Inc.'s approval of two forms of the drug well ahead of their PDUFA dates to treat wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM) left investors in Pfizer and other firms speculating about what the win might mean. Read More
H. Lundbeck A/S, of Copenhagen, has acquired Abide Therapeutics Inc. in a deal designed to strengthen the Danish company's weakened pipeline and establish a research hub in the U.S. Read More
LONDON – Confo Therapeutics NV has raised €30 million (US$33.5 million) in a series A, to scale up drug discovery efforts around its new method of targeting G protein-coupled receptors (GPCRs). Read More
HONG KONG – Chinese clinical-stage cancer drug developer Tot Biopharm International Co. Ltd. has filed an IPO with the Hong Kong Stock Exchange (HKEX), making it the latest pre-revenue applicant for listing on the HKEX, which already has seven pre-profit biotech players listed. Read More
SHANGHAI - Uncertainties over U.S.-China trade relations seem not to have stunted enthusiasm for partnering among a record crowd expected at this year's Chinabio Partnering Forum this week. The annual confab is expected to draw about 1,400 attendees, about 60% from China, with the rest about evenly split between participants from ex-China Asian countries and Western delegates representing U.S. and Europe. Read More
HONG KONG – Edigene Inc., a startup focused on genome editing to develop novel therapeutics for genetic diseases and cancer, has raised a further $10 million during the first half of this year and entered a strategic collaboration with another Chinese biotech. Read More
Scynexis Inc., of Jersey City, N.J., reported data demonstrating the antifungal activity of ibrexafungerp as an agent to address vulvovaginal candidiasis (VVC). The data, which were presented at the 2019 American College of Obstetrics and Gynecology meeting in Nashville, Tenn., further support the company's plan to submit a new drug application for VVC in the second half of 2020. Read More
The U.S. Department of Health and Human Services' (HHS) proposed rule to remove the anti-kickback safe harbor for prescription drug rebates paid to pharmacy benefit managers (PBMs) likely will not result in lower list prices, according to a new Congressional Budget Office (CBO) projection. Read More
Athenex Inc., of Buffalo, N.Y., signed an agreement for the sale of its common stock in a private placement with three institutional investors: Perceptive Advisors, Avoro Capital Advisors (formerly known as Venbio Select Advisor) and Orbimed. Read More
